H Niitani

2.1k total citations
61 papers, 1.8k citations indexed

About

H Niitani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, H Niitani has authored 61 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in H Niitani's work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (23 papers) and Cancer therapeutics and mechanisms (15 papers). H Niitani is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (23 papers) and Cancer therapeutics and mechanisms (15 papers). H Niitani collaborates with scholars based in Japan, Australia and India. H Niitani's co-authors include N Masuda, M. Fukuoka, Kiyoyuki Furuse, Y Ariyoshi, Shunichi Negoro, Yutaka Nishiwaki, Masakichi Motomiya, T Kuriyama, Kazuo Hasegawa and Atsushi Suzuki and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

In The Last Decade

H Niitani

60 papers receiving 1.7k citations

Peers

H Niitani

ONCOL

PRM

EPIDE

SURGE

S. Kudoh Japan

M. Fukuoka Japan

Susan Coughlin United States

A. Mathieu-Boué France

Scott Z. Fields United States

Joseph Michaeli United States

Allyson J. Ocean United States

Hwee‐Yong Yap United States

C. Manegold Germany

Hitoshi Kusaba Japan

S. Kudoh Japan

H Niitani

1.1k ×0.8

ONCOL

832 ×1.0

549 ×0.7

PRM

384 ×2.2

EPIDE

72 ×0.4

SURGE

Citations per year, relative to H Niitani H Niitani (= 1×) peers S. Kudoh

Countries citing papers authored by H Niitani

Since Specialization

Citations

This map shows the geographic impact of H Niitani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Niitani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Niitani more than expected).

Fields of papers citing papers by H Niitani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H Niitani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Niitani. The network helps show where H Niitani may publish in the future.

Co-authorship network of co-authors of H Niitani

This figure shows the co-authorship network connecting the top 25 collaborators of H Niitani. A scholar is included among the top collaborators of H Niitani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H Niitani. H Niitani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Negoro, Shunichi, N Masuda, Y Takada, et al.. (2003). Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. British Journal of Cancer. 88(3). 335–341. 121 indexed citations

Matsumoto, T, Yasuo Ohashi, Satoshi Morita, et al.. (2002). The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): Validity and reliability in Japanese patients with advanced non-small-cell lung cancer. Quality of Life Research. 11(5). 483–493. 35 indexed citations

Furuse, Kiyoyuki, Mutsuto Kawahara, Kosei Hasegawa, et al.. (2001). Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. International Journal of Clinical Oncology. 6(5). 236–241. 30 indexed citations

Kawahara, Minoru, Kiyoyuki Furuse, Yoshihiko Segawa, et al.. (2001). Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. British Journal of Cancer. 85(7). 939–943. 188 indexed citations

Nishiwaki, Yutaka, Shunichi Negoro, Katsuya Watanabe, M. Fukuoka, & H Niitani. (1999). Late phase II trials of topotecan (T) for relapsed small cell lung cancer (SCLC). European Journal of Cancer. 35. S253–S253. 4 indexed citations

Masuda, N, M. Fukuoka, Akihisa Fujita, et al.. (1998). A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. British Journal of Cancer. 78(2). 251–256. 60 indexed citations

Furuse, Kiyoyuki, Kaoru Kubota, Masaaki Kawahara, et al.. (1996). Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer. Oncology. 53(2). 169–172. 58 indexed citations

Furuse, Kiyoyuki, M. Fukuoka, Mutsuo Kuba, et al.. (1996). Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). Annals of Oncology. 7(8). 815–820. 29 indexed citations

Kunitoh, Hideo, Kyohei Watanabe, T Onoshi, et al.. (1996). Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.. Journal of Clinical Oncology. 14(5). 1649–1655. 119 indexed citations

10.

Niitani, H. (1995). [Phase II study].. PubMed. 22(5). 607–10. 132 indexed citations

11.

Niitani, H, Kiyoyuki Furuse, M. Fukuoka, Kazuya Hasegawa, & T Taguchi. (1994). Phase I clinical study on new vinca alkaloid derivative, KW 2307 (vinorelbine). Gan to kagaku ryōhō. 21(2). 177–187. 2 indexed citations

12.

Fukuoka, M., H Niitani, Atsushi Suzuki, et al.. (1992). A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.. Journal of Clinical Oncology. 10(1). 16–20. 374 indexed citations

13.

Azuma, Arata, Hideo Yagita∥, Hiroshi Matsuda, Ko Okumura, & H Niitani. (1992). Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.. PubMed. 52(18). 4890–4. 35 indexed citations

14.

K, Ota, A Wakui, H Majima, et al.. (1992). [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].. PubMed. 19(6). 855–61. 30 indexed citations

15.

Fukuoka, M., N Masuda, Y Kusunoki, et al.. (1991). Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 83(16). 1164–1168. 242 indexed citations

16.

Kobayashi, Ken, et al.. (1991). [Pilot study of multi-cyclic combination chemotherapy in small cell lung cancer].. PubMed. 18(3). 489–92. 1 indexed citations

17.

K, Ota, Y Ariyoshi, M. Fukuoka, Kiyoyuki Furuse, & H Niitani. (1990). [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for lung cancer. rG.CSF Cooperation Study Group].. PubMed. 17(1). 65–71. 10 indexed citations

18.

Saijo, N., et al.. (1983). [Effect of Nocardia rubra cell wall skeleton against pleuritis carcinomatosa in adenocarcinoma of the lung].. PubMed. 10(2 Pt). 290–5. 4 indexed citations

19.

Saijo, Nagahiro, Yutaka Nishiwaki, Ichiro Kawase, et al.. (1978). Effect of ACNU on primary lung cancer, mesothelioma, and metastatic pulmonary tumors.. PubMed. 62(1). 139–41. 9 indexed citations

20.

Shimoyama, M, H Niitani, Toshiyasu Taniguchi, Jiro Inagaki, & Kazuhiro Kimura. (1969). The role of lysosomes in cancer chemotherapy. 3. Influence of plasmin on the lysosomes of tumor cells and on the cytocidal effect of mitomycin-C.. PubMed. 60(1). 33–9. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact